Hexacath, France, announces that TITAN2 the first BAS (Bio Active Stent) has been awarded a level III official reimbursement approval in France.

September 5, 2006 - Barcelona
The information was published in the French Government Journal "Journal Officiel de la République Française" in april 2006. Hexacath is proud to make available to physicians and patients around the world its unique patented Titanium-Nitride-Oxide technology which has been proven to significantly reduce restenosis and MACE (Major Adverse Cardiac Event) at follow up versus Bare Metal Stents.
View document (pdf file, 22Kb)

TITAN stent vs TAXUS stent

October 20, 2005 - Washington DC
Dr Pasi Karjalainen from Satakunta Hospital Pori Hospital in Finland presented the data about the Titan stent Pori Registry during the Cardiovascular Research Foundation's 17th Annual Transcatheter Cardiovascular Therapeutics (TCT 2005) scientific symposia moderated by Dr E.Grube.
View document (pdf file, 19Kb)